Headquartered in Köln and founded in 2003, CEVEC Pharmaceuticals provides cell tech for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale: with a portfolio covering various platform technologies for gene therapy vectors, vector vaccines and complex recombinant proteins. This includes its Elevecta tech for AAV manufacturing, CAP Ad tech for RCA-free adenoviral vectors, and CAP Go for production of complex and highly glycosylated recombinant proteins.
Supporting gene and cell therapies
One of the biggest challenges in cell and gene therapy is establishing production processes that can keep up with the increasing demand for volume and consistent quality of viral vectors. With its scalable producer cell lines for vectors based on adeno-associated Virus (AAV) and adenovirus, CEVEC covers two of the most widely used vectors for delivering therapeutic genes to target cells and tissues.
Producer Cell Lines (PCLs), as enabled by CEVEC's Elevecta technology, enable yield, scalability, and robustness in the manufacturing process. With this tech, all components necessary for vector production are stably integrated into the genome of the PCL, offering an alternative to technologies based on transfection or the use of a helper virus.
CEVEC and its 46 scientific experts will become part of therapeutics technology and service provider Cytiva with immediate effect; and its products, services and technologies will continue to be offered under the Elevecta and CAP brands with worldwide availability.
Emmanuel Abate, President, Genomic Medicine at Massachusetts-headquartered Cytiva, said: "Cevec's innovative technology complements Cytiva's offering and brings the promise of improved viral vector manufacturing.
"With Cytiva's global reach and ability to scale, more customers will have access to Cevec's technology and expertise to help accelerate and advance therapeutics for the benefit of patients."